|
SCFD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63336011382853E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.30684352228627E-12 |
| Normal-vs-Stage2 |
1.190330E-04 |
| Normal-vs-Stage3 |
1.738609256563E-13 |
| Normal-vs-Stage4 |
5.88418203051333E-15 |
| Stage1-vs-Stage2 |
1.626170E-01 |
| Stage1-vs-Stage3 |
4.866000E-02 |
| Stage1-vs-Stage4 |
5.363500E-04 |
| Stage2-vs-Stage3 |
1.472410E-02 |
| Stage2-vs-Stage4 |
1.437500E-03 |
| Stage3-vs-Stage4 |
1.528850E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
6.28040000000274E-05 |
| Normal-vs-Asian |
2.79960055138417E-10 |
| Caucasian-vs-AfricanAmerican |
3.310600E-01 |
| Caucasian-vs-Asian |
7.801800E-01 |
| AfricanAmerican-vs-Asian |
5.125200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.16338058578458E-12 |
| Normal-vs-Female |
1.72972747236599E-12 |
| Male-vs-Female |
3.962200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.54259954704617E-11 |
| Normal-vs-Age(41-60Yrs) |
2.79598566521599E-12 |
| Normal-vs-Age(61-80Yrs) |
2.62379007409663E-12 |
| Normal-vs-Age(81-100Yrs) |
3.416400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.573400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.617000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.116400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.426600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.334400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.723200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.176100E-03 |
| Classical-VS-Follicular |
3.084200E-02 |
| Classical-VS-Other |
4.412000E-01 |
| Classical-VS-Normal |
1.6251444634463E-12 |
| Tall-VS-Follicular |
8.06230000000019E-05 |
| Tall-VS-Other |
5.007800E-01 |
| Tall-VS-Normal |
2.59681165459824E-13 |
| Follicular-VS-Other |
2.302600E-01 |
| Follicular-VS-Normal |
4.3742999999985E-05 |
| Other-VS-Normal |
4.011700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.64279956094538E-10 |
| Normal-vs-N1 |
2.90878432451791E-14 |
| N0-vs-N1 |
1.300550E-03 |
|
|
